ArticleNPJ breast cancer2023

Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival.

Noortje Verschoor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.